Globally, there are hundreds of thousands of people living with X-linked retinitis pigmentosa, a devastating condition that often leads to vision loss in young people. But a new treatment is giving these patients new hope and creating a tremendous growth opportunity for the company behind it.
Our guest today is Lance Baldo MD, who has served as the CEO of Beacon Therapeutics since July of 2024. Before Beacon, Lance was chief medical officer at Freenome, where he led medical strategy from clinical trials through registration and commercialization, and Chief Medical Officer at Adaptive Biotechnologies, where he was part of the senior leadership team as it transitioned from a private to a publicly held company.
Lance is also a medical doctor by training, holding an MD from the University of Connecticut School of Medicine, and a BA in biology from Johns Hopkins University.
Today, he joins us to discuss the extremely exciting results of Beacon’s recent medical trials, navigating the regulatory process on their way to launch, and how their novel gene therapy could help patients with a broad array of ocular diseases.
Highlights:
- How Lance Landed the CEO Job (1:35)
- Gene Therapy for the Eye (3:00)
- Who Is Affected by XLRP (4:15)
- A New Hope for Vision Loss (5:00)
- The Day the Trial Results Came In (8:45)
- Why It Took a Decade to Get Here (11:30)
- Working With Regulators (15:15)
- Getting Ready to Launch (18:00)
- Raising Money as a CEO (21:30)
- Priorities for 2027 (26:15)
Links:
Lance Baldo LinkedIn
Beacon Therapeutics LinkedIn
Feedback:
If you have questions about the show, or have a topic in mind you’d like discussed in future episodes, email our producer, [email protected].
Publisher: Source link









